Philip Ashton-Rickardt
Chief Tech/Sci/R&D Officer bei SIGILON THERAPEUTICS, INC.
Vermögen: - $ am 31.07.2023
Profil
Philip Ashton-Rickardt was the founder of Smith Therapeutics, Inc. (founded in 2017), where he held the titles of President, CEO, Secretary & Director until 2019.
He is currently the Chief Scientific Officer at Sigilon Therapeutics, Inc. (since 2021).
Previously, he worked as the Chairman of Immunology at Imperial College London, Senior Vice President of Immunology at AZTherapies, Inc. (2019-2021), and Associate Professor at The University of Chicago (1995-2006).
Dr. Ashton-Rickardt obtained his doctorate degree from The University of Edinburgh and his undergraduate degree from King's College London.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
11.08.2023 | 0 ( -.--% ) | - $ | 31.07.2023 |
Aktive Positionen von Philip Ashton-Rickardt
Unternehmen | Position | Beginn |
---|---|---|
SIGILON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 14.06.2021 |
Ehemalige bekannte Positionen von Philip Ashton-Rickardt
Unternehmen | Position | Ende |
---|---|---|
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.06.2021 |
Smith Therapeutics, Inc.
Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Smith Therapeutics, Inc. operates as a biopharmaceutical firm which treats neurodegenerative disease. The company was founded by Philip Ashton-Rickardt in 2017 and is headquartered in Chestnut, MA. | Founder | 31.10.2019 |
The University of Chicago | Corporate Officer/Principal | 01.06.2006 |
Imperial College London | Corporate Officer/Principal | - |
Ausbildung von Philip Ashton-Rickardt
The University of Edinburgh | Doctorate Degree |
King's College London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SIGILON THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Health Technology |
Smith Therapeutics, Inc.
Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Smith Therapeutics, Inc. operates as a biopharmaceutical firm which treats neurodegenerative disease. The company was founded by Philip Ashton-Rickardt in 2017 and is headquartered in Chestnut, MA. | Health Technology |